Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 26.29M P/E - EPS this Y 67.70% Ern Qtrly Grth -
Income -30.04M Forward P/E -1.13 EPS next Y -19.60% 50D Avg Chg -3.00%
Sales - PEG -0.11 EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book 0.86 EPS next 5Y 39.60% 52W High Chg -44.00%
Recommedations 2.00 Quick Ratio 2.79 Shares Outstanding 65.47M 52W Low Chg 78.00%
Insider Own 1.68% ROA -50.20% Shares Float 41.55M Beta 1.55
Inst Own 76.73% ROE -110.27% Shares Shorted/Prior 5.42M/54.88K Price 1.35
Gross Margin - Profit Margin - Avg. Volume 29,295 Target Price 6.20
Oper. Margin - Earnings Date May 9 Volume 2,706 Change 0.75%
About Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc. News
03/23/24 Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
03/21/24 Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
03/14/24 Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
03/13/24 Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
03/12/24 Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
03/12/24 Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
01/02/24 Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
11/22/23 Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/09/23 Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
11/02/23 Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
10/19/23 Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
09/20/23 Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
09/13/23 Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
09/05/23 Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
08/24/23 Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?
08/23/23 Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
08/23/23 Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
08/08/23 Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
08/02/23 Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
07/18/23 Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
RGLS Chatroom

User Image billpap Posted - 2 days ago

$RGLS

User Image Venecia Posted - 1 week ago

$RGLS 📝

User Image MoonShine007 Posted - 1 week ago

$RGLS I'm still green, should I doubt up?

User Image vjtweet Posted - 1 week ago

$RGLS 2 bullish possibilities. Given the mkt condition 1. to take trades only after confirmed action and 2. to book quick profits.

User Image ButterCapital Posted - 1 week ago

$RGLS 🦦

User Image Doozio Posted - 1 week ago

$RGLS wen 🧠⏰?

User Image YakoCapital Posted - 2 weeks ago

$RGLS Glad I got out of this yesterday.

User Image DonCorleone77 Posted - 2 weeks ago

$RGLS Regulus files to sell 62.5M shares of common stock for holders

User Image MoonShine007 Posted - 2 weeks ago

$RGLS who added more?

User Image ButterCapital Posted - 2 weeks ago

$RGLS 👏👏

User Image Atore Posted - 3 weeks ago

$RGLS

User Image commoncentsinvestor Posted - 3 weeks ago

$RGLS ONE TO CHECK OUT FOR BIG GAINS IN 2024 Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

User Image MoonShine007 Posted - 3 weeks ago

$RGLS not selling. Rebound soon. Buy more.

User Image lizquita Posted - 3 weeks ago

$RGLS now what?

User Image Pafist Posted - 3 weeks ago

$RGLS $3.00 on the horizon.

User Image ButterCapital Posted - 3 weeks ago

$RGLS

User Image Atore Posted - 3 weeks ago

$RGLS https://youtu.be/P-6m5X3a5iQ?si=0qQZ5LqVHg8MDJEz

User Image Atore Posted - 03/30/24

$RGLS soul nourishment https://youtu.be/Hu16CR5OV3o?si=jczT24Lyo7iRPiJR

User Image Rolex53 Posted - 03/27/24

$RGLS guys $100m placement is more or less similar to $AVTX IMHO. Check the move.

User Image Venecia Posted - 03/27/24

$RGLS Ascending Triagle✔️ Flat Resistance signaling a reliable pattern✔️Possible Breakout coming✔️🤟

User Image BMust Posted - 03/27/24

$CYTO $SOUN $RGLS red to green coming

User Image BMust Posted - 03/26/24

$RGLS like some one said here , big boys will take it to the finish line .

User Image MoonShine007 Posted - 03/26/24

$RGLS slowly study!!!

User Image BMust Posted - 03/26/24

$RGLS

User Image Stocks4thought Posted - 4 weeks ago

$RGLS What is the premise here) _ When I listened to the call it sounded like endpoints were unknown- almost exploratory (discovering a compound- MOA).............anybody help me on this one CKD is huge!!

User Image ButterCapital Posted - 4 weeks ago

$RGLS luv this one

User Image Venecia Posted - 4 weeks ago

$RGLS "Buy" rating reiterated by investment analysts at HC Wainwright, $9 PT. ✔️📝 https://www.marketbeat.com/instant-alerts/nasdaq-rgls-reiterated-rating-2024-03-25/

User Image BMust Posted - 4 weeks ago

$RGLS check this out

User Image BMust Posted - 4 weeks ago

$RGLS PT$9-12 Heavily shorted $100 million private equity financing 3/14 . Tutes hold majority . Highly Promising drug data .load up

User Image BMust Posted - 4 weeks ago

$RGLS another conservative PT$9

Analyst Ratings
HC Wainwright & Co. Buy Mar 25, 24
Canaccord Genuity Buy Mar 19, 24
Leerink Partners Outperform Mar 18, 24
HC Wainwright & Co. Buy Mar 18, 24
Wells Fargo Equal-Weight Mar 13, 24
Canaccord Genuity Buy Sep 21, 23
HC Wainwright & Co. Buy Sep 21, 23
HC Wainwright & Co. Buy Sep 19, 23
HC Wainwright & Co. Buy Aug 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
CALSADA CRISPINA Chief Financial Offi.. Chief Financial Officer Jan 18 Sell 1.1906 5,468 6,510 5,782 01/18/24
Aker Christopher Ray Sr. VP & General Cou.. Sr. VP & General Counsel Jan 18 Sell 1.1906 5,468 6,510 10,056 01/18/24
Hagan Joseph P Chief Executive Offi.. Chief Executive Officer Jan 18 Sell 1.1906 14,580 17,359 57,112 01/18/24
Drygin Denis Chief Scientific Off.. Chief Scientific Officer Feb 04 Buy 0.23 23,314 5,362 23,314 02/07/22
Hagan Joseph P President and CEO President and CEO Jan 12 Buy 0.2152 100,000 21,520 417,006 01/26/22